Koester SK - Search Results

1

Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo.

Sipila PE, Wiebe VJ, Hubbard GB, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, Seymour RC, DeGregorio MW. Sipila PE, et al. Among authors: koester sk. Eur J Cancer. 1993;29A(15):2138-44. doi: 10.1016/0959-8049(93)90049-l. Eur J Cancer. 1993. PMID: 8297653

2

Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Baker WJ, Wiebe VJ, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, DeGregorio MW. Baker WJ, et al. Among authors: koester sk. Breast Cancer Res Treat. 1992;24(1):43-9. doi: 10.1007/BF01832357. Breast Cancer Res Treat. 1992. PMID: 1463871

3

Flow cytometry: potential utility in monitoring drug effects in breast cancer.

Koester SK, Maenpaa JU, Wiebe VJ, Baker WJ, Wurz GT, Seymour RC, Koehler RE, DeGregorio MW. Koester SK, et al. Breast Cancer Res Treat. 1994;32(1):57-65. doi: 10.1007/BF00666206. Breast Cancer Res Treat. 1994. PMID: 7819587 Review.

4

A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin.

Maenpaa JU, Wurz GT, Baker WJ, Wiebe VJ, Emshoff VD, Koester SK, Seymour RC, Koehler RE, DeGregorio MW. Maenpaa JU, et al. Among authors: koester sk. Oncol Res. 1993;5(12):461-6. Oncol Res. 1993. PMID: 8086667

5

Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.

Baker WJ, Maenpaa JU, Wurz GT, Koester SK, Seymour RC, Emshoff VD, Wiebe VJ, DeGregorio MW. Baker WJ, et al. Among authors: koester sk. Oncol Res. 1993;5(6-7):207-12. Oncol Res. 1993. PMID: 8123940

6

A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.

DeGregorio M, Wurz G, Emshoff V, Koester S, Minor P, Wiebe V. DeGregorio M, et al. Breast Cancer Res Treat. 1992;24(1):35-41. doi: 10.1007/BF01832356. Breast Cancer Res Treat. 1992. PMID: 1463870

7

Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance.

Maenpaa J, Wiebe V, Wurz G, Koester S, Emshoff V, Seymour R, DeGregorio M. Maenpaa J, et al. Cancer Chemother Pharmacol. 1994;35(2):149-52. doi: 10.1007/BF00686638. Cancer Chemother Pharmacol. 1994. PMID: 7987992

8

Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.

Maenpaa J, Wiebe V, Koester S, Wurz G, Emshoff V, Seymour R, Sipila P, DeGregorio M. Maenpaa J, et al. Cancer Chemother Pharmacol. 1993;32(5):396-8. doi: 10.1007/BF00735926. Cancer Chemother Pharmacol. 1993. PMID: 8339392

9

Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.

Wiebe V, Koester S, Lindberg M, Emshoff V, Baker J, Wurz G, DeGregorio M. Wiebe V, et al. Invest New Drugs. 1992 Jul;10(2):63-71. doi: 10.1007/BF00873119. Invest New Drugs. 1992. PMID: 1386843

10

Investigation of taxol as a potential radiation sensitizer.

Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Choy H, et al. Cancer. 1993 Jun 1;71(11):3774-8. doi: 10.1002/1097-0142(19930601)71:11<3774::aid-cncr2820711147>3.0.co;2-0. Cancer. 1993. PMID: 8098270

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters